In Vitro Modeling Services for Rare Lung Diseases
In vitro models of rare lung diseases have made significant progress in recent years, mainly in the areas of pulmonary fibrosis, interstitial lung disease (PID), and rare tumors, etc. Protheragen provides new tools and methodologies for the study of the pathogenesis, drug screening, and therapeutic strategies of rare lung diseases through the development of a variety of in vitro models.
Current Challenges in Existing In Vitro Lung Models
Despite relentless efforts to develop in vitro lung models, they have not yet succeeded in developing functional human in vitro models with most of the characteristics of the lung organ. The high throughput and reproducibility of the preclinical development process for organ-on-a-chip technology still needs to be improved. Most in vitro models are based on "proof-of-concept" designs of cell lines that do not mimic the complexity and physiology of native cells and therefore cannot be fully applied to humans.
Figure 1. Biologically inspired design of a human breathing lung-on-a-chip microdevice. (Huh D, et al., 2010） Our Services
Protheragen offers researchers in the field of rare lung diseases a wide range of in vitro modeling services that can provide important support for disease mechanism studies, drug screening and therapeutic strategy development. We can also help you optimize the physiology and functionality of your existing models to increase their value for disease mechanism studies and drug development. In short, we are committed to helping you overcome technical and application challenges to achieve broader clinical translation.
| Types of diseases | Types of in vitro models |
|---|---|
| Idiopathic pulmonary fibrosis | In vitro modeling of TGF-β1-induced 3D lung-like organ model Alveolar macrophage model Co-culture model of immune cells and fibroblasts |
| Lymphangioleiomyomatosis | 3D sphere model |
| Pulmonary alveolar proteinosis | Three-dimensional in vitro lung tissue culture models (LTCs) |
| Pulmonary idiopathic hypertension | Pulmonary artery smooth muscle cells (PASMCs) and pulmonary artery endothelial cells (PAECs) isolated from patients or healthy donors |
| Langerhans cell histiocytosis | Induced Pluripotent Stem Cells (iPSCs) models Xenograft models Spheroid and organoid models |
| Cystic fibrosis | Lung airway organ-on-a-chip model Chronic Pseudomonas aeruginosa infection model |
| Pulmonary atresia | Lung organ chips lung organoid Elastic hydrogel derived from lung elasticity Precision cut lung slices Extracorporeal lung perfusion (EVLP) models |
| Wegener's granulomatosis | Three-dimensional lung tissue organ model (OSGM) Acute lung injury model based on isolated lung tissue Human peripheral blood mononuclear cell granuloma model Multicellular lung tissue model |
Our Techniques for Constructing in Vitro Lung Disease Models
- 2D cell culture technology
- 3D culture technology
- Microfluidic chip technology
- Precision sliced lungs
- 3D Bioprinting
- Organ-on-a-Chip
Advantages of Our Models
- Accurately simulate the physiology and pathology of the lungs
- Rapidly assess the efficacy and toxicity of drug candidates
- Support the development of anti-infective therapies
References
- Doryab A, Groll J. Biomimetic In Vitro Lung Models: Current Challenges and Future Perspective. Adv Mater. 2023;35(13):e2210519.
- Huh D, Matthews BD, Mammoto A, Montoya-Zavala M, Hsin HY, Ingber DE. Reconstituting organ-level lung functions on a chip. Science. 2010;328(5986):1662-1668.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.